The leukotriene B
GPCR
chemotaxis
immune response
inflammation
lipid mediators
wound healing
Journal
Immunological reviews
ISSN: 1600-065X
Titre abrégé: Immunol Rev
Pays: England
ID NLM: 7702118
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
medline:
21
8
2023
pubmed:
14
3
2023
entrez:
13
3
2023
Statut:
ppublish
Résumé
Leukotriene B
Substances chimiques
Leukotriene B4
1HGW4DR56D
Receptors, Leukotriene B4
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
30-41Informations de copyright
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Shimizu T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu Rev Pharmacol Toxicol. 2009;49:123-150.
Cyster JG. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol. 2005;23:127-159.
Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014;510(7503):92-101.
Obinata H, Hla T. Sphingosine 1-phosphate and inflammation. Int Immunol. 2019;31(9):617-625.
Yao C, Narumiya S. Prostaglandin-cytokine crosstalk in chronic inflammation. Br J Pharmacol. 2019;176(3):337-354.
Harayama T, Shimizu T. Roles of polyunsaturated fatty acids, from mediators to membranes. J Lipid Res. 2020;61(8):1150-1160.
Yanagida K, Shimizu T. Lysophosphatidic acid, a simplest lipid with a myriad function. Pharmacol Ther. 2023; in press.
Rouzer CA, Shimizu T, Samuelsson B. On the nature of the 5-lipoxygenase reaction in human leukocytes: characterization of a membrane-associated stimulatory factor. Proc Natl Acad Sci USA. 1985;82(22):7505-7509.
Shimizu T, Honda Z, Miki I, et al. Potato arachidonate 5-lipoxygenase: purification, characterization, and preparation of 5(S)-hydroperoxyeicosatetraenoic acid. Methods Enzymol. 1990;187:296-306.
Shimizu T, Radmark O, Samuelsson B. Enzyme with dual lipoxygenase activities catalyzes leukotriene A4 synthesis from arachidonic acid. Proc Natl Acad Sci USA. 1984;81(3):689-693.
Shimizu T, Radmark O, Samuelsson B. Biosynthesis of leukotriene A4 from 5-hydroperoxyeicosatetraenoic acid: possible involvement of 8-lipoxygenase reaction. Adv Prostaglandin Thromboxane Leukot Res. 1985;15:177-180.
Minami M, Ohno S, Kawasaki H, et al. Molecular cloning of a cDNA coding for human leukotriene A4 hydrolase. Complete primary structure of an enzyme involved in eicosanoid synthesis. J Biol Chem. 1987;262(29):13873-13876.
Funk CD, Radmark O, Fu JY, et al. Molecular cloning and amino acid sequence of leukotriene A4 hydrolase. Proc Natl Acad Sci USA. 1987;84(19):6677-6681.
Lam BK, Penrose JF, Freeman GJ, Austen KF. Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4. Proc Natl Acad Sci USA. 1994;91(16):7663-7667.
Ohishi N, Minami M, Kobayashi J, et al. Immunological quantitation and immunohistochemical localization of leukotriene A4 hydrolase in guinea pig tissues. J Biol Chem. 1990;265(13):7520-7525.
Hopke A, Lin T, Scherer AK, et al. Transcellular biosynthesis of leukotriene B(4) orchestrates neutrophil swarming to fungi. iScience. 2022;25(10):105226.
Folco G, Murphy RC. Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses. Pharmacol Rev. 2006;58(3):375-388.
Haeggstrom JZ, Wetterholm A, Shapiro R, Vallee BL, Samuelsson B. Leukotriene A4 hydrolase: a zinc metalloenzyme. Biochem Biophys Res Commun. 1990;172(3):965-970.
Minami M, Ohishi N, Mutoh H, et al. Leukotriene A4 hydrolase is a zinc-containing aminopeptidase. Biochem Biophys Res Commun. 1990;173(2):620-626.
Toh H, Minami M, Shimizu T. Molecular evolution and zinc ion binding motif of leukotriene A4 hydrolase. Biochem Biophys Res Commun. 1990;171(1):216-221.
Haeggstrom JZ. Leukotriene A4 hydrolase/aminopeptidase, the gatekeeper of chemotactic leukotriene B4 biosynthesis. J Biol Chem. 2004;279(49):50639-50642.
Rudberg PC, Tholander F, Andberg M, Thunnissen MM, Haeggstrom JZ. Leukotriene A4 hydrolase: identification of a common carboxylate recognition site for the epoxide hydrolase and aminopeptidase substrates. J Biol Chem. 2004;279(26):27376-27382.
Snelgrove RJ, Jackson PL, Hardison MT, et al. A critical role for LTA4H in limiting chronic pulmonary neutrophilic inflammation. Science. 2010;330(6000):90-94.
Sumimoto J, Takeshige K, Minakami S. Characterization of human neutrophil leukotriene B4 omega-hydroxylase as a system involving a unique cytochrome P-450 and NADPH-cytochrome P-450 reductase. Eur J Biochem. 1988;172(2):315-324.
Sumimoto H, Minakami S. Oxidation of 20-hydroxyleukotriene B4 to 20-carboxyleukotriene B4 by human neutrophil microsomes. Role of aldehyde dehydrogenase and leukotriene B4 omega-hydroxylase (cytochrome P-450LTB omega) in leukotriene B4 omega-oxidation. J Biol Chem. 1990;265(8):4348-4353.
Yokomizo T, Izumi T, Takahashi T, et al. Enzymatic inactivation of leukotriene B4 by a novel enzyme found in the porcine kidney. Purification and properties of leukotriene B4 12-hydroxydehydrogenase. J Biol Chem. 1993;268(24):18128-18135.
Yokomizo T, Ogawa Y, Uozumi N, Kume K, Izumi T, Shimizu T. cDNA cloning, expression, and mutagenesis study of leukotriene B4 12-hydroxydehydrogenase. J Biol Chem. 1996;271(5):2844-2850.
Yamamoto T, Yokomizo T, Nakao A, Izumi T, Shimizu T. Immunohistochemical localization of Guinea-pig leukotriene B4 12-hydroxydehydrogenase/15-ketoprostaglandin 13-reductase. Eur J Biochem. 2001;268(23):6105-6113.
Ensor CM, Zhang H, Tai HH. Purification, cDNA cloning and expression of 15-oxoprostaglandin 13-reductase from pig lung. Biochem J. 1998;330(Pt 1):103-108.
Okuno T, Iizuka Y, Okazaki H, Yokomizo T, Taguchi R, Shimizu T. 12(S)-Hydroxyheptadeca-5Z, 8E, 10E-trienoic acid is a natural ligand for leukotriene B4 receptor 2. J Exp Med. 2008;205(4):759-766.
Yasukawa K, Okuno T, Ogawa N, Kobayashi Y, Yokomizo T. Identification and characterization of bioactive metabolites of 12-hydroxyheptadecatrienoic acid, a ligand for leukotriene B4 receptor 2. J Biochem. 2022;mvac105. https://doi.org/10.1093/jb/mvac105
Hori T, Yokomizo T, Ago H, et al. Structural basis of leukotriene B4 12-hydroxydehydrogenase/15-oxo-prostaglandin 13-reductase catalytic mechanism and a possible Src homology 3 domain binding loop. J Biol Chem. 2004;279(21):22615-22623.
Hori T, Ishijima J, Yokomizo T, Ago H, Shimizu T, Miyano M. Crystal structure of anti-configuration of indomethacin and leukotriene B4 12-hydroxydehydrogenase/15-oxo-prostaglandin 13-reductase complex reveals the structural basis of broad spectrum indomethacin efficacy. J Biochem. 2006;140(3):457-466.
Smith WL, Urade Y, Jakobsson PJ. Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. Chem Rev. 2011;111(10):5821-5865.
Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352(11):1071-1080.
McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA. 1999;96(1):272-277.
FitzGerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov. 2003;2(11):879-890.
Gilbert NC, Gerstmeier J, Schexnaydre EE, et al. Structural and mechanistic insights into 5-lipoxygenase inhibition by natural products. Nat Chem Biol. 2020;16(7):783-790.
Gilbert NC, Bartlett SG, Waight MT, et al. The structure of human 5-lipoxygenase. Science. 2011;331(6014):217-219.
Ferguson AD, McKeever BM, Xu S, et al. Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein. Science. 2007;317(5837):510-512.
Ago H, Kanaoka Y, Irikura D, et al. Crystal structure of a human membrane protein involved in cysteinyl leukotriene biosynthesis. Nature. 2007;448(7153):609-612.
Weinert T, Olieric V, Waltersperger S, et al. Fast native-SAD phasing for routine macromolecular structure determination. Nat Methods. 2015;12(2):131-133.
Stsiapanava A, Samuelsson B, Haeggstrom JZ. Capturing LTA(4) hydrolase in action: insights to the chemistry and dynamics of chemotactic LTB(4) synthesis. Proc Natl Acad Sci USA. 2017;114(36):9689-9694.
Igarashi T, Yokomizo T, Tsutsumi O, Taketani Y, Shimizu T, Izumi T. Characterization of the leukotriene B4 receptor in porcine leukocytes. Separation and reconstitution with heterotrimeric GTP-binding proteins. Eur J Biochem. 1999;259(1-2):419-425.
Honda Z, Nakamura M, Miki I, et al. Cloning by functional expression of platelet-activating factor receptor from Guinea-pig lung. Nature. 1991;349(6307):342-346.
Nakamura M, Honda Z, Izumi T, et al. Molecular cloning and expression of platelet-activating factor receptor from human leukocytes. J Biol Chem. 1991;266(30):20400-20405.
Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature. 1997;387(6633):620-624.
Noiri E, Yokomizo T, Nakao A, et al. An in vivo approach showing the chemotactic activity of leukotriene B(4) in acute renal ischemic-reperfusion injury. Proc Natl Acad Sci USA. 2000;97(2):823-828.
Obinata H, Yokomizo T, Shimizu T, Izumi T. Glucocorticoids up-regulate leukotriene B4 receptor-1 expression during neutrophilic differentiation of HL-60 cells. Biochem Biophys Res Commun. 2003;309(1):114-119.
Kato K, Yokomizo T, Izumi T, Shimizu T. Cell-specific transcriptional regulation of human leukotriene B(4) receptor gene. J Exp Med. 2000;192(3):413-420.
Yokomizo T, Kato K, Terawaki K, Izumi T, Shimizu T. A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med. 2000;192(3):421-432.
Iizuka Y, Yokomizo T, Terawaki K, Komine M, Tamaki K, Shimizu T. Characterization of a mouse second leukotriene B4 receptor, mBLT2: BLT2-dependent ERK activation and cell migration of primary mouse keratinocytes. J Biol Chem. 2005;280(26):24816-24823.
Masuda K, Yokomizo T, Izumi T, Shimizu T. cDNA cloning and characterization of Guinea-pig leukotriene B4 receptor. Biochem J. 1999;342(Pt 1):79-85.
Toda A, Yokomizo T, Masuda K, Nakao A, Izumi T, Shimizu T. Cloning and characterization of rat leukotriene B(4) receptor. Biochem Biophys Res Commun. 1999;262(3):806-812.
Wang S, Gustafson E, Pang L, et al. A novel hepatointestinal leukotriene B4 receptor. Cloning and functional characterization. J Biol Chem. 2000;275(52):40686-40694.
Tryselius Y, Nilsson NE, Kotarsky K, Olde B, Owman C. Cloning and characterization of cDNA encoding a novel human leukotriene B(4) receptor. Biochem Biophys Res Commun. 2000;274(2):377-382.
Kamohara M, Takasaki J, Matsumoto M, et al. Molecular cloning and characterization of another leukotriene B4 receptor. J Biol Chem. 2000;275(35):27000-27004.
Yokomizo T, Kato K, Hagiya H, Izumi T, Shimizu T. Hydroxyeicosanoids bind to and activate the low affinity leukotriene B4 receptor, BLT2. J Biol Chem. 2001;276(15):12454-12459.
Kuniyeda K, Okuno T, Terawaki K, Miyano M, Yokomizo T, Shimizu T. Identification of the intracellular region of the leukotriene B4 receptor type 1 that is specifically involved in Gi activation. J Biol Chem. 2007;282(6):3998-4006.
Ito N, Yokomizo T, Sasaki T, et al. Requirement of phosphatidylinositol 3-kinase activation and calcium influx for leukotriene B4-induced enzyme release. J Biol Chem. 2002;277(47):44898-44904.
Aratake Y, Okuno T, Matsunobu T, et al. Helix 8 of leukotriene B4 receptor 1 inhibits ligand-induced internalization. FASEB J. 2012;26(10):4068-4078.
Okuno T, Ago H, Terawaki K, Miyano M, Shimizu T, Yokomizo T. Helix 8 of the leukotriene B4 receptor is required for the conformational change to the low affinity state after G-protein activation. J Biol Chem. 2003;278(42):41500-41509.
Ichiki T, Koga T, Okuno T, et al. Modulation of leukotriene B4 receptor 1 signaling by receptor for advanced glycation end products (RAGE). FASEB J. 2016;30(5):1811-1822.
Nakanishi Y, Tan M, Ichiki T, et al. Stepwise phosphorylation of leukotriene B4 receptor 1 defines cellular responses to leukotriene B4. Sci Signal. 2018;11(544):eaao5390.
Nakamura M, Shimizu T. Recent advances in function and structure of two leukotriene B(4) receptors: BLT1 and BLT2. Biochem Pharmacol. 2022;203:115178.
Nakamura M, Shimizu T. Leukotriene receptors. Chem Rev. 2011;111(10):6231-6298.
Wan M, Sabirsh A, Wetterholm A, Agerberth B, Haeggstrom JZ. Leukotriene B4 triggers release of the cathelicidin LL-37 from human neutrophils: novel lipid-peptide interactions in innate immune responses. FASEB J. 2007;21(11):2897-2905.
Terawaki K, Yokomizo T, Nagase T, et al. Absence of leukotriene B4 receptor 1 confers resistance to airway hyperresponsiveness and Th2-type immune responses. J Immunol. 2005;175(7):4217-4225.
Haribabu B, Verghese MW, Steeber DA, Sellars DD, Bock CB, Snyderman R. Targeted disruption of the leukotriene B(4) receptor in mice reveals its role in inflammation and platelet-activating factor-induced anaphylaxis. J Exp Med. 2000;192(3):433-438.
Tager AM, Dufour JH, Goodarzi K, Bercury SD, von Andrian UH, Luster AD. BLTR mediates leukotriene B(4)-induced chemotaxis and adhesion and plays a dominant role in eosinophil accumulation in a murine model of peritonitis. J Exp Med. 2000;192(3):439-446.
Uozumi N, Kume K, Nagase T, et al. Role of cytosolic phospholipase A2 in allergic response and parturition. Nature. 1997;390(6660):618-622.
Medoff BD, Tager AM, Jackobek R, Means TK, Wang L, Luster AD. Antibody-antigen interaction in the airway drives early granulocyte recruitment through BLT1. Am J Physiol Lung Cell Mol Physiol. 2006;290(1):L170-L178.
Goodarzi K, Goodarzi M, Tager AM, Luster AD, von Andrian UH. Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues. Nat Immunol. 2003;4(10):965-973.
Ott VL, Cambier JC, Kappler J, Marrack P, Swanson BJ. Mast cell-dependent migration of effector CD8+ T cells through production of leukotriene B4. Nat Immunol. 2003;4(10):974-981.
Tager AM, Bromley SK, Medoff BD, et al. Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment. Nat Immunol. 2003;4(10):982-990.
Medoff BD, Seung E, Wain JC, et al. BLT1-mediated T cell trafficking is critical for rejection and obliterative bronchiolitis after lung transplantation. J Exp Med. 2005;202(1):97-110.
Taube C, Miyahara N, Ott V, et al. The leukotriene B4 receptor (BLT1) is required for effector CD8+ T cell-mediated, mast cell-dependent airway hyperresponsiveness. J Immunol. 2006;176(5):3157-3164.
Hikiji H, Ishii S, Yokomizo T, Takato T, Shimizu T. A distinctive role of the leukotriene B4 receptor BLT1 in osteoclastic activity during bone loss. Proc Natl Acad Sci USA. 2009;106(50):21294-21299.
Bouchareychas L, Grossinger EM, Kang M, Qiu H, Adamopoulos IE. Critical role of LTB4/BLT1 in IL-23-induced synovial inflammation and Osteoclastogenesis via NF-kappaB. J Immunol. 2017;198(1):452-460.
Shao WH, Del Prete A, Bock CB, Haribabu B. Targeted disruption of leukotriene B4 receptors BLT1 and BLT2: a critical role for BLT1 in collagen-induced arthritis in mice. J Immunol. 2006;176(10):6254-6261.
Mathis SP, Jala VR, Lee DM, Haribabu B. Nonredundant roles for leukotriene B4 receptors BLT1 and BLT2 in inflammatory arthritis. J Immunol. 2010;185(5):3049-3056.
Heller EA, Liu E, Tager AM, et al. Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment. Circulation. 2005;112(4):578-586.
Ahluwalia N, Lin AY, Tager AM, et al. Inhibited aortic aneurysm formation in BLT1-deficient mice. J Immunol. 2007;179(1):691-697.
Saiwai H, Ohkawa Y, Yamada H, et al. The LTB4-BLT1 axis mediates neutrophil infiltration and secondary injury in experimental spinal cord injury. Am J Pathol. 2010;176(5):2352-2366.
Saiwai H, Kumamaru H, Ohkawa Y, et al. Ly6C+ Ly6G- myeloid-derived suppressor cells play a critical role in the resolution of acute inflammation and the subsequent tissue repair process after spinal cord injury. J Neurochem. 2013;125(1):74-88.
Asahara M, Ito N, Yokomizo T, Nakamura M, Shimizu T, Yamada Y. The absence of the leukotriene B4 receptor BLT1 attenuates peripheral inflammation and spinal nociceptive processing following intraplantar formalin injury. Mol Pain. 2015;11(1):11.
Asahara M, Ito N, Hoshino Y, et al. Role of leukotriene B4 (LTB4)-LTB4 receptor 1 signaling in post-incisional nociceptive sensitization and local inflammation in mice. PLoS One. 2022;17(10):e0276135.
Kihara Y, Yokomizo T, Kunita A, et al. The leukotriene B4 receptor, BLT1, is required for the induction of experimental autoimmune encephalomyelitis. Biochem Biophys Res Commun. 2010;394(3):673-678.
Nagatake T, Hirata SI, Koga T, et al. BLT1 mediates commensal bacteria-dependent innate immune signals to enhance antigen-specific intestinal IgA responses. Mucosal Immunol. 2019;12(5):1082-1091.
Shioda R, Jo-Watanabe A, Okuno T, et al. The leukotriene B(4) /BLT1-dependent neutrophil accumulation exacerbates immune complex-mediated glomerulonephritis. FASEB J. 2023;37(2):e22789.
Del Prete A, Shao WH, Mitola S, Santoro G, Sozzani S, Haribabu B. Regulation of dendritic cell migration and adaptive immune response by leukotriene B4 receptors: a role for LTB4 in up-regulation of CCR7 expression and function. Blood. 2007;109(2):626-631.
Miyahara N, Ohnishi H, Matsuda H, et al. Leukotriene B4 receptor 1 expression on dendritic cells is required for the development of Th2 responses and allergen-induced airway hyperresponsiveness. J Immunol. 2008;181(2):1170-1178.
Toda A, Terawaki K, Yamazaki S, Saeki K, Shimizu T, Yokomizo T. Attenuated Th1 induction by dendritic cells from mice deficient in the leukotriene B4 receptor 1. Biochimie. 2010;92(6):682-691.
Zhou J, Lai W, Yang W, et al. BLT1 in dendritic cells promotes Th1/Th17 differentiation and its deficiency ameliorates TNBS-induced colitis. Cell Mol Immunol. 2018;15(12):1047-1056.
Sasaki F, Koga T, Saeki K, et al. Biochemical and immunological characterization of a novel monoclonal antibody against mouse leukotriene B4 receptor 1. PLoS One. 2017;12(9):e0185133.
Zandi S, Nakao S, Chun KH, et al. ROCK-isoform-specific polarization of macrophages associated with age-related macular degeneration. Cell Rep. 2015;10(7):1173-1186.
Sasaki F, Koga T, Ohba M, et al. Leukotriene B4 promotes neovascularization and macrophage recruitment in murine wet-type AMD models. JCI Insight. 2018;3(18):96902.
Werz O, Gerstmeier J, Libreros S, et al. Human macrophages differentially produce specific resolvin or leukotriene signals that depend on bacterial pathogenicity. Nat Commun. 2018;9(1):59.
Koga T, Sasaki F, Saeki K, et al. Expression of leukotriene B4 receptor 1 defines functionally distinct DCs that control allergic skin inflammation. Cell Mol Immunol. 2021;18(6):1437-1449.
Yokomizo T, Nakamura M, Shimizu T. Leukotriene receptors as potential therapeutic targets. J Clin Invest. 2018;128(7):2691-2701.
Yokomizo T, Izumi T, Shimizu T. Co-expression of two LTB4 receptors in human mononuclear cells. Life Sci. 2001;68(19-20):2207-2212.
Iizuka Y, Okuno T, Saeki K, et al. Protective role of the leukotriene B4 receptor BLT2 in murine inflammatory colitis. FASEB J. 2010;24(12):4678-4690.
Ishii Y, Saeki K, Liu M, et al. Leukotriene B4 receptor type 2 (BLT2) enhances skin barrier function by regulating tight junction proteins. FASEB J. 2016;30(2):933-947.
Hara T, Saeki K, Jinnouchi H, Kazuno S, Miura Y, Yokomizo T. The c-terminal region of BLT2 restricts its localization to the lateral membrane in a LIN7C-dependent manner. FASEB J. 2021;35(2):e21364.
Matsumoto Y, Matsuya Y, Nagai K, et al. Leukotriene B4 receptor type 2 accelerates the healing of intestinal lesions by promoting epithelial cell proliferation. J Pharmacol Exp Ther. 2020;373(1):1-9.
Hayashi S, Muraleedharan CK, Oku M, et al. Intestinal epithelial BLT1 promotes mucosal repair. JCI. Insight. 2022;7(23):e162392.
Liu M, Saeki K, Matsunobu T, et al. 12-Hydroxyheptadecatrienoic acid promotes epidermal wound healing by accelerating keratinocyte migration via the BLT2 receptor. J Exp Med. 2014;211(6):1063-1078.
Iwamoto S, Koga T, Ohba M, et al. Non-steroidal anti-inflammatory drug delays corneal wound healing by reducing production of 12-hydroxyheptadecatrienoic acid, a ligand for leukotriene B4 receptor 2. Sci Rep. 2017;7(1):13267.
Shigematsu M, Koga T, Ishimori A, et al. Leukotriene B4 receptor type 2 protects against pneumolysin-dependent acute lung injury. Sci Rep. 2016;6:34560.
Uzawa H, Kohno D, Koga T, et al. Leukotriene A4 hydrolase deficiency protects mice from diet-induced obesity by increasing energy expenditure through neuroendocrine axis. FASEB J. 2020;34(10):13949-13958.
Hosooka T, Hosokawa Y, Matsugi K, et al. The PDK1-FoxO1 signaling in adipocytes controls systemic insulin sensitivity through the 5-lipoxygenase-leukotriene B4 axis. Proc Natl Acad Sci USA. 2020;117(21):11674-11684.
Marder P, Spaethe SM, Froelich LL, et al. Inhibition of ex vivo neutrophil activation by oral LY293111, a novel leukotriene B4 receptor antagonist. Br J Clin Pharmacol. 1996;42(4):457-464.
Liston TE, Conklyn MJ, Houser J, et al. Pharmacokinetics and pharmacodynamics of the leukotriene B4 receptor antagonist CP-105,696 in man following single oral administration. Br J Clin Pharmacol. 1998;45(2):115-121.
Showell HJ, Conklyn MJ, Alpert R, et al. The preclinical pharmacological profile of the potent and selective leukotriene B4 antagonist CP-195543. J Pharmacol Exp Ther. 1998;285(3):946-954.
Alten R, Gromnica-Ihle E, Pohl C, et al. Inhibition of leukotriene B4-induced CD11B/CD18 (mac-1) expression by BIIL 284, a new long acting LTB4 receptor antagonist, in patients with rheumatoid arthritis. Ann Rheum Dis. 2004;63(2):170-176.
Evans DJ, Barnes PJ, Spaethe SM, van Alstyne EL, Mitchell MI, O'Connor BJ. Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma. Thorax. 1996;51(12):1178-1184.
Van Pelt JP, De Jong EM, Seijger MM, et al. Investigation on a novel and specific leukotriene B4 receptor antagonist in the treatment of stable plaque psoriasis. Br J Dermatol. 1998;139(3):396-402.
Mommers JM, Van Rossum MM, Kooijmans-Otero ME, Parker GL, van de Kerkhof PC. VML 295 (LY-293111), a novel LTB4 antagonist, is not effective in the prevention of relapse in psoriasis. Br J Dermatol. 2000;142(2):259-266.
Schwartz GK, Weitzman A, O'Reilly E, et al. Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors. J Clin Oncol. 2005;23(23):5365-5373.
Baetz T, Eisenhauer E, Siu L, et al. A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours. Invest New Drugs. 2007;25(3):217-225.
Saif MW, Oettle H, Vervenne WL, et al. Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas. Cancer J. 2009;15(4):339-343.
Janne PA, Paz-Ares L, Oh Y, et al. Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer. J Thorac Oncol. 2014;9(1):126-131.
Diaz-Gonzalez F, Alten RH, Bensen WG, et al. Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66(5):628-632.
Konstan MW, Doring G, Heltshe SL, et al. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. J Cyst Fibros. 2014;13(2):148-155.
Chiang N, Serhan CN, Dahlen SE, et al. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev. 2006;58(3):463-487.
Luo L, Tanaka R, Kanazawa S, et al. A synthetic leukotriene B4 receptor type 2 agonist accelerates the cutaneous wound healing process in diabetic rats by indirect stimulation of fibroblasts and direct stimulation of keratinocytes. J Diabetes Complications. 2017;31(1):13-20.
Hernandez-Olmos V, Heering J, Planz V, et al. First structure-activity relationship study of potent BLT2 agonists as potential wound-healing promoters. J Med Chem. 2020;63(20):11548-11572.
Hori T, Okuno T, Hirata K, et al. Na(+)-mimicking ligands stabilize the inactive state of leukotriene B4 receptor BLT1. Nat Chem Biol. 2018;14(3):262-269.
Wang N, He X, Zhao J, et al. Structural basis of leukotriene B4 receptor 1 activation. Nat Commun. 2022;13(1):1156.